Measurement of mycophenolic acid in plasma or serum by a commercial enzyme inhibition technique in comparison with a high performance liquid chromatography method
Authors:
- 1 January 2008
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 46 (9) , 1281-4
Abstract
Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant mycophenolate mofetil. High performance liquid chromatography (HPLC) is commonly used for therapeutic drug monitoring (TDM) of MPA but requires batched runs. Recently, an enzyme inhibition assay (EIA) was approved for MPA TDM on random-access platforms using either serum or EDTA plasma. We evaluated the EIA on a Roche Integra 400 using serum and heparinized plasma in comparison with a validated HPLC method.: Heparinized plasma from leftover clinical samples on which MPA was ordered along with paired serum samples, drawn at the same time for other clinical tests, were used for the method comparison.: The EIA was linear from 3.1 to 44.0 μmol/L with an accuracy of 93.9%–107.1%. The intra- and inter-day variations were 0.5%–2.7% and 1.6%–2.1%, respectively. The limit of detection was 0.8 μmol/L and the limit of quantification was 3.1 μmol/L. The method showed a mean bias of 0.6 μmol/L (7.6%) in serum samples (3.1–34.1 μmol/L) vs. the HPLC method using paired plasma (n=229). Heparinized plasma (n=114) vs. serum showed a mean bias of –0.1 μmol/L (–1.6%) by the EIA.: The random-access EIA on Integra 400 is acceptable for clinical MPA TDM in either serum or heparinized plasma.Clin Chem Lab Med 2008;46:1281–4.Keywords
This publication has 19 references indexed in Scilit:
- Therapeutic drug measurement of mycophenolic acid derivatives in transplant patientsClinical Biochemistry, 2007
- Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney TransplantationAmerican Journal of Transplantation, 2005
- Mechanisms of Action of Mycophenolate Mofetil in Preventing Acute and Chronic Allograft RejectionTransplantation, 2005
- Determinants of Mycophenolic Acid Levels After Renal TransplantationTherapeutic Drug Monitoring, 2005
- Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic rangeLiver Transplantation, 2004
- Mycophenolate Mofetil for Solid Organ Transplantation: Does the Evidence Support the Need for Clinical Pharmacokinetic Monitoring?Therapeutic Drug Monitoring, 2003
- Mycophenolic acid pharmacokinetics in pediatric liver transplant recipientsLiver Transplantation, 2003
- Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acidClinical Biochemistry, 1998
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- Mechanism of Action of Mycophenolate MofetilTherapeutic Drug Monitoring, 1995